Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies
Trial details
- Registry ID
- NCT04933721
- Drugs studied
- berotralstat
TrialRedline tracks 11 clinical trials sponsored by BioCryst Pharmaceuticals: 4 Phase 3, 2 Phase 2 / 3, 5 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat StudiesNCT04933721 | berotralstat | Enrolling by invitation | 2031-08Estimated |
| Berotralstat Treatment in Children With Hereditary AngioedemaNCT05453968 | Berotralstat | Active not recruiting | 2024-09-11Actual |
| Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in JapanNCT03873116 | BCX7353 capsules | Completed | 2021-07-08Actual |
| Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAENCT03485911 | BCX7353 capsules | Completed | 2019-04-10Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Long Term Safety Study of BCX7353 in Hereditary AngioedemaNCT03472040 | BCX7353 | Completed | 2022-04-27Actual |
| 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE AttacksNCT02303626 | BCX4161 | Completed | 2016-01Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal HemoglobinuriaNCT05741346 | BCX9930 | Terminated | 2025-01-31Actual |
| A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)NCT04702568 | BCX9930, Eculizumab, Ravulizumab | Terminated | 2023-10-04Actual |
| BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor TherapyNCT05116787 | BCX9930 monotherapy | Terminated | 2023-09-18Actual |
| BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor TherapyNCT05116774 | BCX9930, Eculizumab, Ravulizumab | Terminated | 2023-09-14Actual |
| Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)NCT05162066 | BCX9930 | Terminated | 2022-09-23Actual |
Names as written in the registry records.
NCT05453968 · BioCryst Pharmaceuticals
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Pharmacokinetics: Cmax Measure: Pharmacokinetics: AUC0-tau Measure: Pharmacokinetics: CL/F. After: Measure: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of Berotralstat Measure: Area Under the Plasma Concentration-Time Curve From Time 0 to 6 Hours Post-dose (AUC0-6) of Berotralstat Measure: Concentration at the End of the Dosing Interval (Ctrough) of Berotralstat Measure: Maximum Observed Plasma Concentration (Cmax) of Berotralstat Measure: Time of Last Measurable Plasma Concentration (Tlast) of Berotralstat Measure: Time to Maximum Plasma Concentration (Tmax) of Berotralstat.
NCT04933721 · BioCryst Pharmaceuticals
Before: Active not recruiting. After: Enrolling by invitation.